Literature DB >> 18247358

Probing the interaction between p53 and the bacterial protein azurin by single molecule force spectroscopy.

Monia Taranta1, Anna Rita Bizzarri, Salvatore Cannistraro.   

Abstract

p53 is a human tumour suppressor which regulates multiple cellular processes, including cell growth, genomic stability and cell death. Recent works have demonstrated the bacterial redox protein azurin to enter cancer cells and induce apoptosis through p53 stabilization, resulting in a tumour growth regression. Azurin has been shown to bind p53 although many details of the complex formed by these two proteins are still poorly characterized. Here, we get insight into the kinetics of this complex formation, by exploring the interaction between p53 and azurin in their environment by single molecule force spectroscopy. To this aim, azurin has been linked to the atomic force microscope tip, whereas p53 has been immobilized onto a gold substrate. Therefore, by performing force-distance cycles we have detected specific recognition events between p53 and azurin, displaying unbinding forces of around 70 pN for an applied loading rate of 3 nN s(-1). The specificity of these events has been assessed by the significant reduction of their frequency observed after blocking the p53 sample by an azurin solution. Moreover, by measuring the rupture force as a function of the loading rate we have determined the dissociation rate constant of this complex to be approximately 0.1 s(-1). Our findings are here discussed in connection with results obtained in bulk experiments, with the aim of clarifying some molecular details of the p53-azurin complex that may help designing new anticancer strategy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18247358     DOI: 10.1002/jmr.869

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  18 in total

Review 1.  Single-molecule dynamics and mechanisms of metalloregulators and metallochaperones.

Authors:  Peng Chen; Aaron M Keller; Chandra P Joshi; Danya J Martell; Nesha May Andoy; Jaime J Benítez; Tai-Yen Chen; Ace George Santiago; Feng Yang
Journal:  Biochemistry       Date:  2013-10-01       Impact factor: 3.162

Review 2.  Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.

Authors:  Meng Gao; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  Protein Sci       Date:  2017-10-27       Impact factor: 6.725

Review 3.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

4.  A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.

Authors:  Greg S Gorman; Lori U Coward; Lea Freeman; Pat E Noker; Craig W Beattie; Lee Jia
Journal:  J Pharm Biomed Anal       Date:  2010-06-30       Impact factor: 3.935

5.  Variation in the mechanical unfolding pathway of p53DBD induced by interaction with p53 N-terminal region or DNA.

Authors:  Yukinori Taniguchi; Masaru Kawakami
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

6.  SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor.

Authors:  Fabio Domenici; Anna Rita Bizzarri; Salvatore Cannistraro
Journal:  Int J Nanomedicine       Date:  2011-09-19

7.  Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.

Authors:  Anna Rita Bizzarri; Simona Santini; Emilia Coppari; Monica Bucciantini; Silvia Di Agostino; Tohru Yamada; Craig W Beattie; Salvatore Cannistraro
Journal:  Int J Nanomedicine       Date:  2011-11-24

8.  Discovery of Azurin-Like Anticancer Bacteriocins from Human Gut Microbiome through Homology Modeling and Molecular Docking against the Tumor Suppressor p53.

Authors:  Chuong Nguyen; Van Duy Nguyen
Journal:  Biomed Res Int       Date:  2016-04-30       Impact factor: 3.411

9.  p28, a first in class peptide inhibitor of cop1 binding to p53.

Authors:  T Yamada; K Christov; A Shilkaitis; L Bratescu; A Green; S Santini; A R Bizzarri; S Cannistraro; T K D Gupta; C W Beattie
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640

10.  A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.

Authors:  Emilia Coppari; Tohru Yamada; Anna Rita Bizzarri; Craig W Beattie; Salvatore Cannistraro
Journal:  Int J Nanomedicine       Date:  2014-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.